EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSOKIG00005049503
Gene Symbol: GABRG2
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOKIG00005042003
Gene Symbol: GABRG3
1 Cross references
214 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOKIG00005016618
Gene Symbol: GABRG3
3 Cross references
211 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOKIG00005028801
Gene Symbol: GABRG3
3 Cross references
211 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOKIG00005031600
Gene Symbol: GABBR1
3 Cross references
183 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOKIG00005019029
Gene Symbol: GABBR1
3 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOKIG00005035825
Gene Symbol: GABBR1
3 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOKIG00005030996
Gene Symbol: GABBR1
1 Cross references
179 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSOKIG00005009485
Gene Symbol: LOC109904662
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSOKIG00005018182
Gene Symbol: LOC109907190
3 Cross references
202 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSOKIG00005033277
Gene Symbol: LOC109876979
2 Cross references
183 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSOKIG00005017675
Gene Symbol: LOC109877603
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).